Achilles Therapeutics shares skyrocket 32% after massive cost cuts—Is this the turnaround it needs?
Achilles Therapeutics PLC saw its American Depositary Receipts (ADRs) soar by an impressive 32%, reflecting renewed investor optimism following the company’s recent announcement of stringent ... Read More
FDA approves Iovance’s AMTAGVI: A breakthrough in melanoma treatment
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a trailblazer in the field of biotechnology focused on developing novel polyclonal tumor infiltrating lymphocyte (TIL) cell therapies, has made ... Read More
Moderna, Merck announce promising results for mRNA-4157 and Keytruda in melanoma
Moderna, Inc. (NASDAQ: MRNA) and Merck (NYSE: MRK), also known as MSD outside the United States and Canada, today revealed follow-up data from their collaborative ... Read More
Moderna, Merck get FDA breakthrough status for mRNA-4157/V940, KEYTRUDA combo in melanoma
Moderna and Merck announced that the investigational personalized mRNA cancer vaccine mRNA-4157/V940 in combination with the latter’s lung cancer drug KEYTRUDA (pembrolizumab) has been given ... Read More
ImmVira wraps up first dosing for MVR-T3011 in US and China
ImmVira said that it has wrapped up the first dosing of its oncolytic virus product - MVR-T3011 intratumoral injection in phase 2 clinical trials both ... Read More
OncoSec Medical begins phase 2 trial for TAVO and OPDIVO combination in melanoma treatment
OncoSec Medical, a US-based biotechnology company, has officially dosed the first patient in its phase 2 clinical trial, OMS-104, aimed at evaluating the combination of ... Read More
Soligenix all set to begin FLASH clinical trial for SGX301 in CTCL
US biopharma company Soligenix has wrapped up enrolling patients for its phase 3 Fluorescent Light Activated Synthetic Hypericin clinical trial (FLASH clinical trial) for SGX301 ... Read More
EC approves Novartis’ skin cancer therapy combo Tafinlar and Mekinist for melanoma
In a significant development for melanoma treatment, the European Commission (EC) has granted Novartis approval for its combination therapy of Tafinlar (dabrafenib) and Mekinist (trametinib). ... Read More